Ambar Faridi, M.D., and Ogul Uner, M.D., discuss their study exploring how using multiple anti-bias tools can help increase diversity among residents of ophthalmology. In contrast, they find that standardized interviews of residency applicants don’t lead to increased diversity; Faridi says standardized interviews can limit informal conversations about applicant resiliency and life experiences.

The Oregonian re-publishes a Kaiser Family Foundation story on patients who have toxic reactions to a form of chemotherapy due to a deficiency in an enzyme that metabolizes the drug. The Oregonian notes that OHSU has followed through on all the terms of the settlement agreement, including various educational efforts for employees and fellows as well as discussion of the deficiency as part of obtaining informed consent from patients.

OPB's "All Science, No Fiction" covers recent OHSU research that finds people may receive as much as a four-fold increase in immune response when they alternate from one arm to the other when receiving a multi-dose vaccine.

In this Q&A interview, Shivaani Kummar, M.D., discusses the mechanism of action of rezatapopt; early efficacy data observed with this agent across solid tumors, including in patients with ovarian cancer; and potential next steps for the future evaluation of TP53-directed drugs in solid tumors.

OHSU researchers collaborate with a team from the University of California Davis to review U.S. dementia study results from the last 10 years to gain a comprehensive picture of what health care access and quality has been like for people living with the condition. They find Black, Latino and Asian families face significantly more challenges getting either a diagnosis or targeted treatment for a loved one living with dementia than white families do.

The OHSU Brain Institute webpage on Cushing's syndrome is also cited in an Ok! Magazine article on actress Amy Schumer's recent diagnosis.

Shivaani Kummar, M.D., discusses the evaluation of the drug rezatapopt for patients with advanced solid tumors in a video interview with OncLive, as well as a Q&A interview. She says: "I’ve been doing drug development for over 20 years. I find that at this point, we are at one of the most exciting times in this field, as we can now design molecules against molecular targets within cancer cells, and we have a slew of different types of agents that target the tumor microenvironment and immune cells."

Responding to a new study suggesting blood-based liquid biopsy tests would result in worse outcomes at an increased cost, David Lieberman, M.D., co-authors a commentary in Clinical Gastroenterology and Hepatology, noting, "Because liquid biopsy is predicted to be less effective and more costly than currently established screening programs, it cannot be recommended to replace established effective screening methods."

In an Everyday Health article on the symptoms of Cushing's syndrome, Maria Fleseriu, M.D., says, "Importantly, not all patients have all of them."

A press release from U.S. Sens. Jeff Merkley and Ron Wyden notes the recently passed Congressional funding package includes $1.142 million to help OHSU and St. Charles Health establish a new psychiatry residency program in Bend, and $2 million for an innovative OHSU demonstration project that aims to improve nurse education and retention.